Literature DB >> 11927798

Transdermal clonidine skin reactions.

L Michael Prisant1.   

Abstract

The clonidine transdermal therapeutic system is being used as a therapy for blood pressure treatment. Systemic side effects seem to be fewer than with oral clonidine. However, localized skin reactions occur frequently and the incidence increases with the dose and duration of use. Common signs include erythema, scaling, vesiculation, excoriation, and induration. Allergic contact dermatitis is less frequent but common. Hyperpigmentation and depigmentation also occur. Pretreatment with 0.5% hydrocortisone is associated with less skin irritation and higher blood levels. Although oral clonidine is no longer widely used in the management of hypertension, awareness of these reactions to the transdermal delivery of this agent is important. (c)2002 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927798      PMCID: PMC8099223          DOI: 10.1111/j.1524-6175.2001.00954.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  29 in total

1.  Transdermal clonidine for the treatment of essential hypertension.

Authors:  J A McChesney; C Ryan; R E Shaw; J Fishman-Rosen; M C Murphy
Journal:  Compr Ther       Date:  1987-04

2.  Allergic contact dermatitis with transdermal clonidine.

Authors:  J C Boekhorst
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

3.  Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension.

Authors:  J R Horning; E T Zawada; J L Simmons; L Williams; R McNulty
Journal:  Chest       Date:  1988-05       Impact factor: 9.410

4.  Skin reactions to long-term transdermal clonidine.

Authors:  J B Dick; D B Northridge; A A Lawson
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

5.  Skin depigmentation related to transdermal clonidine therapy.

Authors:  N Doe; S Seth; L A Hebert
Journal:  Arch Intern Med       Date:  1995-10-23

6.  Transdermal clonidine for hypertension.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1985-10-25       Impact factor: 1.909

7.  Rebound hypertension after discontinuation of transdermal clonidine therapy.

Authors:  S Metz; C Klein; N Morton
Journal:  Am J Med       Date:  1987-01       Impact factor: 4.965

8.  Transdermal administration of clonidine for treatment of high BP.

Authors:  M A Weber; J I Drayer; F G McMahon; R Hamburger; A R Shah; L N Kirk
Journal:  Arch Intern Med       Date:  1984-06

9.  Transdermal clonidine as an adjunct to nifedipine-GITS therapy in patients with mild-to-moderate hypertension.

Authors:  M C Houston; L Hays
Journal:  Am Heart J       Date:  1993-10       Impact factor: 4.749

10.  Long-term treatment with transdermal clonidine in mild hypertension.

Authors:  J M Fillingim; K M Matzek; E M Hughes; P A Johnson; G S Sharon
Journal:  Clin Ther       Date:  1989 May-Jun       Impact factor: 3.393

View more
  4 in total

1.  Drug delivery systems for treatment of systemic hypertension.

Authors:  L Michael Prisant; William J Elliott
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.

Authors:  Jeffrey L Cummings; Martin R Farlow; Xiangyi Meng; Sibel Tekin; Jason T Olin
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Antihypertensive pharmacobezoar.

Authors:  L Michael Prisant; Vernon C Spaulding
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

4.  Transdermal clonidine: therapeutic considerations.

Authors:  Domenic A Sica; Rebecca Grubbs
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-09       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.